A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2018
Price : $35 *
At a glance
- Drugs Rovatirelin (Primary)
- Indications Spinocerebellar degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 27 May 2016 According to Kissei Pharmaceutical media release, company aims at submitting a marketing authorization application of KPS-0373 within this year.
- 15 Apr 2016 Status changed from recruiting to completed.
- 05 Nov 2013 New trial record